Cuproptosis-Related Gene – SLC31A1, FDX1 and ATP7B – Polymorphisms are Associated with Risk of Lung Cancer

Yuhui Yun1,*, Yun Wang2,*, Ende Yang1, Xin Jing1

1Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi’an, Shaanxi, 710038, People’s Republic of China; 2Department of Medical Oncology, Tangdu Hospital, The Fourth Military Medical University, Xi’an, Shaanxi, 710038, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Xin Jing; Ende Yang, Email jingxintd2014@163.com; endeyangfmmu@163.com

Background: Cuproptosis is a novel copper-dependent cell death, and the copper level was increased in lung cancer patients. However, few studies evaluated the association between single-nucleotide polymorphisms (SNPs) in cuproptosis-related genes and lung cancer risk.

Methods: Six SNPs of the SLC31A1, FDX1 and ATP7B genes were genotyped in a case–control cohort including 650 lung cancer cases and 650 controls using the MassARRAY platform.

Results: The minor alleles of SLC31A1-rs10981694 and FDX1-rs10488764 were associated with an increased risk of lung cancer (rs10981694: OR=1.455, 95% CI: 1.201–1.763, p<0.001; rs10488764: OR=1.483, 95% CI: 1.244–1.768, p<0.001). In contrast, the minor alleles of rs9535826 and rs9535828 in ATP7B were related to a decreased risk of the disease (rs9535826: OR=0.714, 95% CI: 0.608–0.838, p<0.001; rs9535828: OR=0.679, 95% CI: 0.579–0.796, p<0.001). The frequencies of rs10981694-TG/GG and rs10488764-GA/AA genotypes were significantly higher in lung cancer cases than that in controls, making them risk genotypes for the disease (p<0.001); while the rs9535826-TG/GG and rs9535828-GA/AA genotypes were protective genotypes and associated with a reduced risk of the disease (p<0.001). Genetic model evaluation revealed that SLC31A1-rs10981694 and FDX1-rs10488764 were associated with a growing risk of lung cancer in dominant, recessive and log-additive models (p<0.001). Moreover, rs9535826 and rs9535828 in ATP7B were related to a declining risk of the disease in three genetic models (p<0.001). In addition, stratification analysis showed that FDX1-rs10488764 was risk variant for lung cancer in both smokers and nonsmokers, and was associated with risk of each pathological type of lung cancer (p<0.008).

Conclusion: The results shed new light on the correlation between cuproptosis-related genes and risk of lung cancer.

Keywords: lung cancer, single-nucleotide polymorphisms, SNPs, solute carrier family 31 member 1, SLC31A1, ferredoxin 1, FDX1, ATPase copper transporting beta, ATP7B

Introduction

Lung cancer is a malignant tumor with the highest morbidity and mortality in China.1,2 The early stage of lung cancer generally has no specific clinical manifestations. Almost 70% of the patients were diagnosed at an advanced stage and even with distant metastasis, and lost the best treatment chance.3 Therefore, early detection, diagnosis, and treatment is the key to reducing the mortality and improving prognosis of the disease. Sufficient research evidence has identified a number of risk factors for lung cancer, including smoking, second-hand smoke, occupational exposure to asbestos and silica, indoor and atmospheric air pollution, and so on.4,5 At the same time, with the wide application of molecular biology technology in recent years, the effect of individual gene susceptibility on the risk of lung cancer has also been verified.6,7 The genetic predisposition to lung cancer is mainly involved in the high-frequency low-penetrance mutation caused by single-nucleotide polymorphisms (SNPs) and low-frequency high-penetrance mutation caused by driver gene
 mutation. Therefore, in-depth development and exploration of SNPs is helpful to screen genetic high-risk group and provide them genetic counseling, and therefore contributing to the early detection and diagnosis of the lung cancer.

Cuproptosis is a copper-dependent and mitochondrial respiration-related cell death, which is different from known death mechanisms such as apoptosis, pyroptosis and ferroptosis. The copper level was found to be increased in lung cancer patients, which could promote tumor angiogenesis, progression and metastasis. Therefore, investigation of cuproptosis-related genes in patients with lung cancer could be of great significance. A recent study has found that cuproptosis was realized by the combination of copper and lipoxylated components in the cycle of tricarboxylic acid, which led to the lipoxylated protein aggregation and subsequent iron–sulfur cluster protein loss, resulting in protein toxic stress and cell death. The ferredoxin 1 (FDX1) encodes a small iron–sulfur protein that transfers electrons from NADPH through ferredoxin reductase to mitochondrial cytochrome P450, which is an upstream regulator for lipoxylation and essential for copper ionophore–induced cell death. The solute carrier family 31 member 1 (SLC31A1) is a high-affinity copper transporter in the cell membrane, function as a homotrimer to affect the uptake of dietary copper. In addition, ATPase copper transporting beta (ATP7B) generally acts as a copper-transporting ATPase which exports copper out of the cells. Previous studies mainly focused on the role of these three genes in copper metabolism disorder (Wilson disease), and the platinum resistance in cancer patients treated with platinum drugs. However, little research evaluated the association between SNPs in the three genes and risk of lung cancer.

Considering the essential role exerted by copper and cuproptosis in the onset and development of lung cancer, we selected six SNPs on SLC31A1, FDX1 and ATP7B based on the previous studies, and genotyped these polymorphisms in our case–control cohort, and assessed their association with risk of lung cancer. rs2233914 in SLC31A1 was related to better prognosis and longer survival time in lung cancer patients treated with platinum drugs. rs10981694 in SLC31A1 was correlated with cisplatin-related toxicity in lung cancer patients after cisplatin treatment. Moreover, FDX1-rs10488764-AA genotype was found to be associated with an elevated risk of IgA nephropathy. In addition, rs1061472, rs9535826 and rs9535828 in ATP7B were investigated in the gastrointestinal toxicity of lung cancer patients treated with platinum-based chemotherapy. None of these studies directly evaluated the associations between these SNPs and risk of lung cancer, especially in different pathological types. We hope our genotyping results could provide new clues for the role of cuproptosis-related genes in the pathogenesis of lung cancer.

Materials and Methods

Subjects
A total of 650 lung cancer patients and 650 healthy controls were included in this study. All subjects were of Chinese Han ethnicity and were recruited at Tangdu Hospital. The patients were diagnosed with lung cancer by histopathological examination of biopsy specimens. The control group included randomly selected healthy individuals with no history of cancer. All participants provided written informed consent. This study was approved by the Ethics Committee of Tangdu Hospital and carried out in accordance with the World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects.

Genotyping
Six SNPs in the cuproptosis-related genes SLC31A1, FDX1 and ATP7B were chosen for genotyping based on previous association studies. The minor allele frequencies (MAFs) of these SNPs are ≥5% in East Asian populations according to the NCBI database. DNA was extracted using a QIAamp DNA Blood Midi Kit (QIAGEN, Germany). Primers were designed using Sequenom MassARRAY Assay Design 3.0 software. SNP genotyping was performed on a Mass ARRAY iPLEX platform (Sequenom, San Diego, CA, USA).

Statistical Analysis
Statistical analysis was performed with SPSS package version 20.0 (SPSS, Chicago, IL, USA). The MAFs of each SNP were checked for divergence from the Hardy–Weinberg equilibrium (HWE). HaploReg v4.1 (https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php) was used to predict the potential functions of the SNPs. Allele and genotype frequencies in the cases and controls were evaluated using Chi-square tests. The association between SNPs and lung cancer risk was evaluated using SNPstats (https://www.snpstats.net/start.htm) and expressed by odds ratios (ORs) and
95% confidence intervals (CIs) with adjustments for sex, age and smoking status. All p values were Bonferroni corrected, and statistical significance was set at $p \leq 0.008$ (0.05/6).

**Results**

The demographic characteristics of the participants are listed in Table 1, including sex, age, smoking status and pathological types. No significant differences were observed in the distributions of sex, age and smoking status between the case and control groups ($p > 0.05$). The pathological types of cases mainly included adenocarcinoma, squamous cell carcinoma and small cell lung cancer, with a percentage of 46.2%, 31.2% and 18.8%, respectively. In addition, 3.8% of the patients were other types of lung cancer.

The basic information and predicted functions of candidate SNPs are described in Table 2. The predicted function according to the HaploReg database showed that rs2233914 and rs10981694 in SLC31A1, rs10488764 in FDX1, and

| Table 1 The Demographic Characteristics of the Participants |
|-----------------------------------------------|
| Characteristics | Case (n=650) | Control (n=650) | $\chi^2/t$ | $p$ |
|-----------------|-------------|----------------|----------|-----|
| Sex (%)         |             |                |          |     |
| Male            | 418 (64.3)  | 415 (63.8)     | 0.030    | 0.862 |
| Female          | 232 (35.7)  | 235 (36.2)     |          |     |
| Age             |             |                | 0.688    | 0.337 |
| Mean ±SD        | 56.91±10.17 | 56.36±10.26    |          |     |
| Smoking (%)     |             |                | 0.030    | 0.862 |
| Yes             | 415 (63.8)  | 412 (63.4)     |          |     |
| No              | 235 (36.2)  | 238 (36.6)     |          |     |
| Pathological types |         |                |          |     |
| Adenocarcinoma  | 300 (46.2)  |                |          |     |
| Squamous cell carcinoma | 203 (31.2) |          |          |     |
| Small cell lung cancer | 122 (18.8) |              |          |     |
| Others          | 25 (3.8)    |                |          |     |

| Table 2 Basic Information and Predicted Functions of Candidate SNPs |
|----------------------|----------------|----------------|-------------|-----------------|
| SNP                  | Gene           | Position       | Allele      | Region          | Predicted Functions                                |
| rs2233914            | SLC31A1        | chr:11:13221260 | G>A         | 2kB Upstream Variant | Promoter histone marks, DNase, Motifs changed, eQTLhits |
| rs10981694           | SLC31A1        | chr:11:13221260 | T>G         | Intron Variant   | DNAse, Motifs changed, Selected eQTLhits            |
| rs10488764           | FDX1           | chr:11:110460907 | G>A         | Intron Variant   | Motifs changed, eQTLhits                           |
| rs1061472            | ATP7B          | chr:13:51950352 | T>C         | Missense Variant | Lys832Arg                                           |
| rs9535826            | ATP7B          | chr:13:519991990 | T>G         | Intron Variant   | Enhancer histone marks, Motifs changed, eQTLhits |
| rs9535828            | ATP7B          | chr:13:51999286 | G>A         | Intron Variant   | Promoter/Enhancer histone marks, DNase, Motifs changed, eQTLhits |

**Abbreviations:** SNP, single-nucleotide polymorphism; eQTL, expression quantitative trait locus.
rs9535826 and rs9535828 in ATP7B were involved in promoter/enhancer histone marks, DNAse, motifs changed and eQTL hits, making it a potential function on the regulation of the gene expression. Moreover, rs1061472 in ATP7B was a missense variant, and led to Lys832Arg.

The MAFs of candidate SNPs between cases and controls are presented in Table 3. All of the SNPs were consistent with HWE (p > 0.05). We compared the MAF of each SNP between the two groups and found that two SNPs were associated with an increased risk of lung cancer, and other two SNPs were protective factors for the disease. The minor alleles of SLC31A1-rs10981694 and FDX1-rs10488764 were associated with a 1.455-fold and 1.483-fold increased risk of lung cancer, respectively (rs10981694: 95% CI: 1.201–1.763, p<0.001; rs10488764: 95% CI: 1.244–1.768, p<0.001).

In contrast, the minor alleles of rs9535826 and rs9535828 in ATP7B were related to a decreased risk of the disease (rs9535826: OR=0.714, 95% CI: 0.608–0.838, p<0.001; rs9535828: OR=0.679, 95% CI: 0.579–0.796, p<0.001).

The genotype frequency distributions between cases and controls are shown in Table 4. The frequencies of rs10981694-TG/GG genotypes were significantly higher in lung cancer cases than that in controls, making them risk genotypes for the disease (p = 0.0005). Similarly, the rs10488764-GA/AA genotypes were also related to an elevated risk of lung cancer (p<0.0001). By contrast, the frequencies of rs9535826-TG/GG and rs9535828-GA/AA genotypes were lower in cases than in controls, which made them become protective genotypes and associated with a reduced risk of the disease (p<0.0002).

The effect of SNPs on the risk of lung cancer was further evaluated using three genetic models (Table 5). The results were consistent with allelic and genotypic results. The SLC31A1-rs10981694 and FDX1-rs10488764 were associated with a growing risk of lung cancer in dominant, recessive and log-additive models (rs10981694: p<0.0001; rs10488764: p<0.0001). In addition, rs9535826 and rs9535828 in ATP7B were related to a declining risk of the disease in three genetic models (rs9535826: p<0.0001; rs9535828: p<0.0001).

Considering that smoking could be a potential risk factor and the different pathogenesis in various pathological types of lung cancer, stratification analysis according to smoking status and different pathological types were further performed (Tables 6 and 7). The FDX1-rs10488764 remained risk variant for lung cancer in both smokers and nonsmokers, and was associated with risk of each pathological type of lung cancer (p<0.008). In addition, the rs9535828 in ATP7B was still a protective factor for the disease whether smoking or not (p<0.008). However, SLC31A1-rs10981694 was only associated with squamous cell carcinoma and small cell lung cancer (p<0.008), and rs9535826 was not a protective variant for the risk of squamous cell carcinoma, which may be due to the limited sample size or the different pathogenesis.

### Table 3 The MAF and HWE of Candidate SNPs Between Lung Cancer Cases and Healthy Controls

| SNP         | Gene      | MAF-Case | MAF-Control | HWE p   | OR (95% CI) | p     |
|-------------|-----------|----------|-------------|---------|-------------|-------|
| rs2233914   | SLC31A1   | 0.35     | 0.33        | 0.86    | 1.075(0.914–1.264) | 0.385 |
| rs10981694  | SLC31A1   | 0.24     | 0.17        | 0.22    | 1.455(1.201–1.763) | 0.00012* |
| rs10488764  | FDX1      | 0.30     | 0.23        | 0.57    | 1.483(1.244–1.768) | 0.00001* |
| rs1061472   | ATP7B     | 0.41     | 0.40        | 0.46    | 1.066(0.911–1.247) | 0.424 |
| rs9535826   | ATP7B     | 0.32     | 0.40        | 0.19    | 0.714(0.608–0.838) | 0.00004* |
| rs9535828   | ATP7B     | 0.34     | 0.43        | 0.75    | 0.679(0.579–0.796) | 0.00001* |

Note: *Bonferroni multiple adjustment was applied, with p ≤ 0.008.

Abbreviations: SNP, single-nucleotide polymorphism; MAF, minor allele frequency; HWE, Hardy–Weinberg equilibrium.
Copper and cuproptosis is closely related to the genesis, severity, and progression of cancer, making it a vulnerable point to target for cancer prevention and treatment. In this study, we focused on cuproptosis-related gene polymorphisms in lung cancer patients and healthy controls, and identified two risk variants (SLC31A1-rs10981694 and FDX1-rs10488764) and two protective mutations (rs9535826 and rs9535828 in ATP7B) for lung cancer. The results broadened our knowledge on the effects of cuproptosis-related gene polymorphisms on the risk of lung cancer and provided new clues for the screening of high-risk population and early detection and diagnosis of the disease.

**SLC31A1** encodes the copper transporter 1 (CTR1) that belongs to the copper transporter family, playing an essential role in regulating the copper homeostasis and affecting the cisplatin and carboplatin uptake in human cells. Barresi et al reported that the mRNA level of SLC31A1 was significantly increased in colorectal carcinoma samples, which was accompanied by a series of elevated expression of copper metabolism-related genes, such as ATP7A, SCO1 and COX11. Moreover, the high levels of SLC31A1 were successively found in prostate cancer, hepatocellular carcinoma and pancreatic cancer, which drew researchers’ attention on the role of SLC31A1 in cancer development. Yu et al found that inhibition of SLC31A1 and blockage of copper absorption caused an elevated mitochondrial ROS level and reduced ATP level in pancreatic cancer cells, and led to an increased autophagy to resist the cell death. In addition, Wu et al demonstrated that ZNF711 could recruit the JHDM2A to the promoter and SLC31A1 and activate its expression, resulting in an enhancement of cisplatin uptake in epithelial ovarian cancer.

| Model     | Genotype | Control (Genotype) | Case (Genotype) | OR (95% CI) | p     |
|-----------|----------|--------------------|-----------------|-------------|-------|
| rs2233914 | GG       | 290 (44.6%)        | 269 (41.4%)     | 1           | 0.47  |
|           | GA       | 287 (44.1%)        | 308 (47.4%)     | 1.15 (0.92–1.46) |       |
|           | AA       | 73 (11.2%)         | 73 (11.2%)      | 1.08 (0.75–1.55) |       |
| rs10981694| TT       | 438 (67.4%)        | 377 (58%)       | 1           | 0.0005*|
|           | TG       | 197 (30.3%)        | 240 (36.9%)     | 1.44 (1.12–1.84) |       |
|           | GG       | 15 (2.3%)          | 33 (5.1%)       | 2.57 (1.37–4.82) |       |
| rs10488764| GG       | 392 (60.3%)        | 318 (48.9%)     | 1           | <0.0001*|
|           | GA       | 222 (34.1%)        | 271 (41.7%)     | 1.52 (1.21–1.92) |       |
|           | AA       | 15 (2.3%)          | 61 (9.4%)       | 2.15 (1.39–3.34) |       |
| rs1061472 | TT       | 242 (37.2%)        | 226 (34.8%)     | 1           | 0.67  |
|           | TC       | 302 (46.5%)        | 314 (48.3%)     | 1.11 (0.87–1.42) |       |
|           | CC       | 106 (16.3%)        | 110 (16.9%)     | 1.10 (0.80–1.53) |       |
| rs9535826 | TT       | 224 (34.5%)        | 291 (44.8%)     | 1           | 0.0002*|
|           | TG       | 329 (50.6%)        | 296 (45.5%)     | 0.69 (0.55–0.88) |       |
|           | GG       | 97 (14.9%)         | 63 (9.7%)       | 0.50 (0.35–0.72) |       |
| rs9535828 | GG       | 207 (31.9%)        | 285 (43.9%)     | 1           | <0.0001*|
|           | GA       | 324 (49.9%)        | 287 (44.1%)     | 0.49 (0.37–0.64) |       |
|           | AA       | 119 (18.3%)        | 78 (12%)        | 0.30 (0.20–0.45) |       |

**Note:** *Bonferroni multiple adjustment was applied, with p ≤ 0.008.
**Abbreviations:** SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

**Discussion**
Copper and cuproptosis is closely related to the genesis, severity, and progression of cancer, making it a vulnerable point to target for cancer prevention and treatment. In this study, we focused on cuproptosis-related gene polymorphisms in lung cancer patients and healthy controls, and identified two risk variants (SLC31A1-rs10981694 and FDX1-rs10488764) and two protective mutations (rs9535826 and rs9535828 in ATP7B) for lung cancer. The results broadened our knowledge on the effects of cuproptosis-related gene polymorphisms on the risk of lung cancer and provided new clues for the screening of high-risk population and early detection and diagnosis of the disease.

SLC31A1 encodes the copper transporter 1 (CTR1) that belongs to the copper transporter family, playing an essential role in regulating the copper homeostasis and affecting the cisplatin and carboplatin uptake in human cells. Barresi et al reported that the mRNA level of SLC31A1 was significantly increased in colorectal carcinoma samples, which was accompanied by a series of elevated expression of copper metabolism-related genes, such as ATP7A, SCO1 and COX11. Moreover, the high levels of SLC31A1 were successively found in prostate cancer, hepatocellular carcinoma and pancreatic cancer, which drew researchers’ attention on the role of SLC31A1 in cancer development. Yu et al found that inhibition of SLC31A1 and blockage of copper absorption caused an elevated mitochondrial ROS level and reduced ATP level in pancreatic cancer cells, and led to an increased autophagy to resist the cell death. In addition, Wu et al demonstrated that ZNF711 could recruit the JHDM2A to the promoter and SLC31A1 and activate its expression, resulting in an enhancement of cisplatin uptake in epithelial ovarian cancer. As for the polymorphisms in SLC31A1, Fujita et al identified that rs10981694 A>C was correlated with a poorer prognosis in esophageal cancer patients treated with neoadjuvant chemoradiotherapy.
with ABCG2 rs1871744, which are associated with poor response in lung cancer patients receiving platinum-based chemotherapy. In this study, we genotyped rs10981694 and rs2233914 polymorphisms in our case–control cohort, and found that SLC31A1-rs10981694 is an independent risk variant for each pathological type of lung cancer, suggesting its

| SNP       | Model     | Genotype | Control | Case  | OR (95% CI) | p   |
|-----------|-----------|----------|---------|-------|-------------|-----|
| rs2233914 | Dominant  | GG       | 290 (44.6%) | 269 (41.4%) | 1.14 (0.91–1.42) | 0.250 |
|           |           | GA-AA    | 360 (55.4%) | 381 (58.6%) |              |     |
|           | Recessive | GG-GA    | 577 (88.8%) | 577 (88.8%) | 1             | 1.000 |
|           |           | AA       | 73 (11.2%)  | 73 (11.2%)  | 1.00 (0.71–1.41) |     |
|           | Log-additive | —     | —       | —     | 1.08 (0.91–1.27) | 0.390 |
| rs10981694| Dominant  | TT       | 438 (67.4%) | 377 (58%)  | 1             | 0.250 |
|           |           | TG-GG    | 212 (32.6%) | 273 (42%)  | 1.52 (1.20–1.93) |     |
|           | Recessive | TT-TG    | 635 (97.7%) | 617 (94.9%) | 1             | 0.250 |
|           |           | GG       | 15 (2.3%)   | 33 (5.1%)   | 1.00 (0.71–1.41) |     |
|           | Log-additive | —     | —       | —     | 1.50 (1.22–1.84) | 0.0001* |
| rs10488764| Dominant  | GG       | 392 (60.3%) | 318 (48.9%) | 1             | <0.0001* |
|           |           | GA-AA    | 258 (39.7%) | 332 (51.1%) | 1.61 (1.29–2.01) |     |
|           | Recessive | GG-GA    | 614 (94.5%) | 589 (90.6%) | 1             | 0.006* |
|           |           | AA       | 36 (5.5%)   | 61 (9.4%)   | 1.81 (1.18–2.78) |     |
|           | Log-additive | —     | —       | —     | 1.49 (1.25–1.78) | <0.0001* |
| rs1061472 | Dominant  | TT       | 242 (37.2%) | 226 (34.8%) | 1             | 0.370 |
|           |           | TC-CC    | 408 (62.8%) | 424 (65.2%) | 1.11 (0.88–1.39) |     |
|           | Recessive | TT-TC    | 544 (83.7%) | 540 (83.1%) | 1             | 0.790 |
|           |           | CC       | 106 (16.3%) | 110 (16.9%) | 1.04 (0.78–1.39) |     |
|           | Log-additive | —     | —       | —     | 1.06 (0.91–1.24) | 0.450 |
| rs9535826 | Dominant  | TT       | 224 (34.5%) | 291 (44.8%) | 1             | 0.0002* |
|           |           | TG-GG    | 426 (65.5%) | 359 (55.2%) | 0.65 (0.52–0.81) |     |
|           | Recessive | TT-TG    | 553 (85.1%) | 587 (90.3%) | 1             | 0.0043* |
|           |           | GG       | 97 (14.9%)  | 63 (9.7%)   | 0.61 (0.44–0.86) |     |
|           | Log-additive | —     | —       | —     | 0.70 (0.60–0.83) | <0.0001* |
| rs9535828 | Dominant  | GG       | 207 (31.9%) | 285 (43.9%) | 1             | <0.0001* |
|           |           | GA-AA    | 443 (68.2%) | 365 (56.1%) | 0.46 (0.35–0.60) |     |
|           | Recessive | GG-GA    | 531 (81.7%) | 572 (88%)  | 1             | 0.0002* |
|           |           | AA       | 119 (18.3%) | 78 (12%)   | 0.53 (0.38–0.74) |     |
|           | Log-additive | —     | —       | —     | 0.54 (0.44–0.65) | <0.0001* |

Note: *Bonferroni multiple adjustment was applied, with p ≤ 0.008.

Abbreviations: SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval.
important role in the onset of the disease in addition to the cisplatin resistance. Considering the function of SLC31A1 in copper transport and cuproptosis, we supposed that rs10981694 may alter the normal function of SLC31A1 and the cuproptosis in patients with lung cancer. However, the detailed mechanisms need to be explored in the further studies.

FDX1 and FDX2 are two homologous ferredoxins in the human mitochondria. Previous studies on the function of these two ferredoxins have been controversial. Sheftel et al reported that FDX1 and FDX2 had distinct roles: FDX1 only participated in the biosynthesis of steroid hormones, whereas FDX2 contributed to the production of heme A and Fe−S cluster formation. Subsequently, Shi et al found that knock-out of FDX1 decreased the enzyme activity of iron–sulfur cluster and affected iron homeostasis, and demonstrated that both FDX1 and FDX2 were closely involved in the formation of Fe−S cluster. Cai et al further proved the important function of FDX1 in the biosynthesis process of Fe−S cluster using nuclear magnetic resonance spectroscopy. More recently, Tsvetkov identified FDX1 could rescue the cell death induced by elesclomol using CRISPR-Cas9 screening, and further revealed that FDX1 specifically promoted the copper-dependent cell death. Specifically, FDX1 could target the six important components in lipoic acid pathway, including LIPT1, LIAS, DLD, DLAT, PDHA1 and PHDB; and it is also a key mediator of protein lipoylation, making it an important promoting factor for cuproptosis. However, little information is found about the correlation between FDX1 and lung cancer.

Table 6 Association Between rs10981694, rs10488764, rs9535826 and rs9535828 and Risk of Lung Cancer in Smokers and Nonsmokers

| SNP       | Model       | Genotype | Smokers |          |          | Nonsmokers |          |
|-----------|-------------|----------|---------|----------|----------|------------|----------|
|           |             |          | OR (95% CI) | p       | OR (95% CI) | p       |
| rs10981694| Dominant    | TT       | 1       | 0.057    | 1        | 0.0016*    |
|           |             | TG-GG    | 1.45 (1.02–2.08) | 1.86 (1.26–2.73) |          |          |
|           | Recessive   | TT-TG    | 1       | 0.040    | 1        | 0.048      |
|           |             | GG       | 1.99 (0.92–4.31) | 2.72 (0.95–7.77) |          |          |
|           | Log-additive|         | 1.42 (1.06–1.90) | 1.79 (1.27–2.52) | 0.0006*   |
| rs10488764| Dominant    | GG       | 1       | 0.010    | 1        | 0.0034*    |
|           |             | GA-AA    | 1.61 (1.21–2.14) | 1.75 (1.20–2.55) |          |          |
|           | Recessive   | GG-GA    | 1       | 0.240    | 1        | 0.0039*    |
|           |             | AA       | 1.39 (0.80–2.41) | 2.68 (1.33–5.40) |          |          |
|           | Log-additive|         | 1.44 (1.14–1.81) | 1.66 (1.24–2.21) | 0.0005*   |
| rs9535826 | Dominant    | TT       | 1       | 0.028    | 1        | 0.0008*    |
|           |             | TG-GG    | 0.73 (0.55–0.97) | 0.52 (0.36–0.77) |          |          |
|           | Recessive   | TT-TG    | 1       | 0.064    | 1        | 0.027      |
|           |             | GG       | 0.66 (0.43–1.03) | 0.55 (0.32–0.94) |          |          |
|           | Log-additive|         | 0.76 (0.62–0.94) | 0.61 (0.47–0.81) | 0.0004*   |
| rs9535828 | Dominant    | GG       | 1       | <0.0001* | 1        | 0.100      |
|           |             | GA-AA    | 0.27 (0.18–0.40) | 0.72 (0.49–1.06) |          |          |
|           | Recessive   | GG-GA    | 1       | 0.004*   | 1        | 0.0087*    |
|           |             | AA       | 0.50 (0.32–0.81) | 0.53 (0.32–0.86) |          |          |
|           | Log-additive|         | 0.32 (0.24–0.45) | 0.72 (0.55–0.93) | 0.011     |

Note: *Bonferroni multiple adjustment was applied, with p ≤ 0.008.
Abbreviations: SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval.
et al reported that FDX1 was not directly related to cell growth or apoptosis, but it did promote the ATP production and take part in the metabolism of glucose, fatty acid and amino acid in lung adenocarcinoma. In the present study, we determined that FDX1-rs10488764 was a risk polymorphism for lung cancer in both smokers and nonsmokers, and three different pathological types subgroups, which shed new light on the role of FDX1 on the development of the disease.

ATP7B is an essential copper-transporting protein that regulates copper transportation from cytosol to Golgi apparatus or lysosomes to maintain copper homeostasis. Generally, ATP7B transfers copper to the Golgi network, whereas the high copper level alters the localization of ATP7B to lysosomes, resulting in a release of copper by vesicle transport. Yang et al reported that the expression of ATP7B was significantly correlated with tumor cell differentiation in lung cancer. Moreover, Li et al demonstrated that ATP7B expression was closely linked to the overall survival and treatment response in lung cancer patients receiving platinum-based chemotherapy. As for polymorphisms in ATP7B, most of studies focused on its association with chemotherapeutic drug response in patients with cancer. In the early stage, Fukushima-Uesaka et al detected a total of 61 genetic variations on ATP7B in Japanese cancer patients and provided reference allele frequencies for other similar studies on Asian populations. Subsequently, Schmid et al identified that loss of heterozygosity of the ATP7B exhibited a better response in patients

| SNP          | Model       | Genotype | Adenocarcinoma OR (95% CI) | p       | Squamous Cell Carcinoma OR (95% CI) | p       | Small Cell Lung Cancer OR (95% CI) | p       |
|--------------|-------------|----------|---------------------------|---------|-----------------------------------|---------|-----------------------------------|---------|
| rs10981694   | Dominant    | TT       | 1                         | 0.048   | I                                 | 0.0001* | I                                 | 0.024   |
|              |             | TG-GG    | 1.35 (1.00–1.81)           | 2.06 (1.44–2.96) | 1.67 (1.07–2.59) |
|              | Recessive   | TT-TG    | 1                         | 0.027   | I                                 | 0.07    | I                                 | 0.015   |
|              |             | GG       | 2.31 (1.11–4.83)           | 2.21 (0.96–5.09) | 3.26 (1.34–7.93) |
|              | Log-additive| —        | 1.37 (1.07–1.77)           | 1.86 (1.38–2.53) | 0.0001* | 1.70 (1.18–2.46) | 0.005* |
| rs10488764   | Dominant    | GG       | 1                         | 0.0021* | I                                 | 0.0098  | I                                 | 0.0006* |
|              |             | GA-AA    | 1.55 (1.17–2.05)           | 1.53 (1.11–2.12) | 2.00 (1.34–2.96) |
|              | Recessive   | GG-GA    | 1                         | 0.22    | I                                 | 0.006*  | I                                 | 0.058   |
|              |             | AA       | 1.42 (0.82–2.45)           | 2.70 (1.56–4.68) | 1.97 (1.01–3.85) |
|              | Log-additive| —        | 1.40 (1.12–1.75)           | 1.56 (1.22–2.00) | 0.0005* | 1.72 (1.27–2.31) | 0.0005* |
| rs9535826    | Dominant    | TT       | 1                         | 0.0013* | I                                 | 0.18    | I                                 | 0.0048* |
|              |             | TG-GG    | 0.63 (0.47–0.83)           | 0.80 (0.57–1.11) | 0.56 (0.38–0.84) |
|              | Recessive   | TT-TG    | 1                         | 0.006*  | I                                 | 0.29    | I                                 | 0.015   |
|              |             | GG       | 0.54 (0.34–0.85)           | 0.77 (0.47–1.26) | 0.44 (0.22–0.91) |
|              | Log-additive| —        | 0.67 (0.54–0.83)           | 0.83 (0.65–1.06) | 0.13 | 0.60 (0.44–0.82) | 0.0011* |
| rs9535828    | Dominant    | GG       | <0.0001*                  | I                                 | 0.0022* | I                                 | <0.0001* |
|              |             | GA-AA    | 0.46 (0.33–0.64)           | 0.52 (0.34–0.79) | 0.36 (0.22–0.59) |
|              | Recessive   | GG-GA    | 1                         | 0.0041* | I                                 | 0.0035* | I                                 | 0.049   |
|              |             | AA       | 0.55 (0.36–0.84)           | 0.48 (0.28–0.80) | 0.53 (0.27–1.03) |
|              | Log-additive| —        | 0.55 (0.43–0.71)           | <0.0001* | 0.52 (0.38–0.72) | <0.0001* | 0.46 (0.31–0.67) | <0.0001* |

Note: *Bonferroni multiple adjustment was applied, with p ≤ 0.008.
Abbreviations: SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval.
with bladder cancer after platinum-based chemotherapy.\(^1\) In addition, Li et al genotyped ATP7B rs1061472 and rs9535826 polymorphisms on ATP7B in 427 lung cancer patients and reported that individuals with rs9535826-GG genotype exhibited a lower gastrointestinal toxicity after platinum-based chemotherapy.\(^20\) We genotyped rs1061472, rs9535826 and rs9535828 on ATP7B in our case–control cohort and found that rs9535826 and rs9535828 were independent protective factors the lung cancer. Considering the overload copper status in cancer, we supposed that rs9535826 and rs9535828 polymorphisms may be essential for maintain the normal function of ATP7B and copper homeostasis.

Recently, the latest association studies on lung cancer have provided us some novel research directions. Ji et al have reported that rs1948915 in lncRNA CCAT1 was correlated with risk of lung adenocarcinoma.\(^42\) Liu et al have found that EGFL7/miR-126 polymorphism rs2297538 was associated with the risk of non-small cell lung cancer.\(^4\) In addition, Yu et al have identified a novel regQTL-SNP, rs3768617, may have effects on lung cancer risk by influencing the expression of miRNA-548b-3p and LAMC1.\(^44\) These studies remind us that we could also explore the association between SNPs in cuproptosis-related lncRNA, miRNA and lung cancer risk, and might identify some novel regQTL-SNP related to lung cancer risk in further studies. There are some intrinsic in our study. Firstly, the subjects were enrolled in a very long time period, we did not detect the copper level of the subjects from the very beginning; therefore, the interaction between polymorphisms in the three genes and the copper level could not be evaluated. Secondly, there are many other potential risk factors for lung cancer, such as alcohol consumption, occupational exposure and air pollution. We did not evaluate the interaction between these factors and candidate SNPs due to the limited information. Thirdly, the present association study could only provide clues for the association between polymorphisms in SLC31A1, FDX1 and ATP7B and risk of lung cancer, but not fully reveal the underlying mechanism. The detailed molecular mechanism needs to be confirmed in tissue samples, cell experiments and animal models.

In conclusion, we found that SLC31A1-rs10981694 and FDX1-rs10488764 were associated with an elevated risk of lung cancer, while rs9535826 and rs9535828 in ATP7B were related to a declining risk of the disease. The results shed new light on the correlation between cuproptosis-related genes and risk of lung cancer, and provided novel reference information for the early detection and diagnosis of the disease.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. *CA Cancer J Clin*. 2016;66(2):115–132.
2. Cao M, Chen W. Epidemiology of lung cancer in China. *Thorac Cancer*. 2019;10(1):3–7.
3. Donington JS, Kim YT, Tong B, et al. Progress in the management of early-stage non-small cell lung cancer in 2017. *J Thorac Oncol*. 2018;13(6):767–778.
4. Schubath MB, Cote ML. Cancer progress and priorities: lung cancer. *Cancer Epidemiol Biomark Prev*. 2019;28(10):1563–1579.
5. Akhtar N, Bansal JG. Risk factors of lung cancer in nonsmoker. *Curr Probl Cancer*. 2017;41(5):328–339.
6. Cannon-Albright LA, Carr SR, Akerley W. Population-based relative risks for lung cancer based on complete family history of lung cancer. *J Thorac Oncol*. 2019;14(7):1184–1191.
7. McKay JD, Hung RJ, Han Y, et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. *Nat Genet*. 2017;49(7):1126–1132.
8. Maya I, Basel-Salmon L, Singer A, Sagi-Dain L. High-frequency low-penetrance copy-number variant classification: should we revise the existing guidelines? *Genet Med*. 2020;22(7):1276–1277.
9. Tang D, Chen X, Kroemer G. Cuproptosis: a copper-triggered modality of mitochondrial cell death. *Cell Res*. 2022;32(5):417–418.
10. Zhang X, Yang Q. Association between serum copper levels and lung cancer risk: a meta-analysis. *J Int Med Res*. 2018;46(12):4863–4873.
11. Oliveri V. Selective targeting of cancer cells by copper ionophores: an overview. *Front Mol Biosci*. 2022;9:841814.
12. Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. *Science*. 2022;375(6586):1254–1261.
13. Kilari D, Guancial E, Kim ES. Role of copper transporters in platinum resistance. *World J Clin Oncol*. 2016;7(1):106–113.
14. Pantoom S, Pomorski A, Huth K, et al. Direct interaction of ATP7B and LC3B proteins suggests a cooperative role of copper transportation and autophagy. *Cells*. 2021;10:11.
15. Collins CJ, Yi F, Dayuha R, et al. Direct measurement of ATP7B peptides is highly effective in the diagnosis of Wilson disease. *Gastroenterology*. 2021;160(7):2367–2382.e2361.
16. Fujita K, Motoyama S, Sato Y, et al. Effects of SLC31A1 and ATP7B polymorphisms on platinum resistance in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy. *Med Oncol*. 2021;38(1):6.
17. Sun C, Zhang Z, Qie J, et al. Genetic polymorphism of SLC31A1 is associated with clinical outcomes of platinum-based chemotherapy in non-small-cell lung cancer patients through modulating microRNA-mediated regulation. Oncotarget. 2018;9(35):23860–23877.

18. Xu X, Ren H, Zhou B, et al. Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 2012;77(2):438–442.

19. Niu D, Gao Y, Xie L, et al. Genetic polymorphisms in TNFSF13 and FXD1 are associated with IgA nephropathy in the Han Chinese population. Hum Immunol. 2015;76(11):831–835.

20. Li YQ, Zhang XY, Chen J, Yin JY, Li XP. ATP7B rs9535826 is associated with gastrointestinal toxicity of platinum-based chemotherapy in nonsmall cell lung cancer patients. J Cancer Res Ther. 2018;14(4):881–886.

21. Li XP, Yin JY, Wang Y, et al. The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients. Tumour Biol. 2014;35(8):8259–8265.

22. Shanbhag VC, Gudekar N, Jasmer K, Papageorgiou C, Singh K, Petris MJ. Copper metabolism as a unique vulnerability in cancer. Biochim Biophys Acta Mol Cell Res. 2021;1868(2):11893.

23. Wee NK, Weinstein DC, Fraser ST, Assinder SJ. The mammalian copper transporters CTR1 and CTR2 and their roles in development and disease. Int J Biochem Cell Biol. 2013;45(5):960–963.

24. Ishida S, McCormick F, Smith-McCune K, Hanahan D. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell. 2010;17(6):574–583.

25. Barresi V, Trovato-Salinaro A, Spampinato G, et al. Transcriptome analysis of copper homeostasis genes reveals coordinated upregulation of SLC31A1, COX11 and COX11 in colorectal cancer. FEBS Open Bio. 2016;6(8):794–806.

26. Safi R, Nelson ER, Chitneni SK, et al. Copper signaling axis as a target for prostate cancer therapeutics. Cancer Res. 2014;74(20):5819–5831.

27. Wachsmann M, Peng F. Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinoma. World J Gastroenterol. 2016;22(1):221–231.

28. Yu Z, Zhou R, Zhao Y, et al. Blockage of SLC31A1-dependent copper absorption increases pancreatic cancer cell autophagy to resist cell death. Cell Prolif. 2019;52(2):e12568.

29. Wu G, Peng H, Tang M, et al. ZNF711 down-regulation promotes CISPLATIN resistance in epithelial ovarian cancer via interacting with JHDM2A and suppressing SLC31A1 expression. EBioMedicine. 2021;71:103558.

30. Wang L, Sun C, Li X, et al. A pharmacogenetics study of platinum-based chemotherapy in lung cancer: ABCG2 polymorphism and its genetic interaction with SLC31A1 are associated with response and survival. J Cancer. 2021;12(5):1270–1283.

31. Sheftel AD, Stehling O, Pierik AJ, et al. Humans possess two mitochondrial ferredoxins, Fdx1 and Fdx2, with distinct roles in steroidogenesis, heme, and Fe/S cluster biosynthesis. Proc Natl Acad Sci U S A. 2010;107(26):11775–11780.

32. Shi Y, Ghosh M, Kovutnovych G, Crooks DR, Rouault TA. Both human ferredoxins 1 and 2 and ferredoxin reductase are important for iron-sulfur cluster biogenesis. Biochim Biophys Acta. 2012;1823(2):484–492.

33. Cai K, Tonelli M, Frederick RO, Markley JL. Human mitochondrial Ferredoxin 1 (FDX1) and Ferredoxin 2 (FDX2) both bind cysteine desulfurase and donate electrons for iron-sulfur cluster biosynthesis. Biochemistry. 2017;56(3):487–499.

34. Tsvetkov P, Detappe A, Cai K, et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019;15(7):681–689.

35. Zhang Z, Ma Y, Guo X, et al. FDX1 can impact the prognosis and mediate the metabolism of lung adenocarcinoma. Front Pharmacol. 2021;12:749134.

36. Polishchuk EV, Concilli M, Iacobacci S, et al. Wilson disease protein ATP7B utilizes lysosomal exocytosis to maintain copper homeostasis. Dev Cell. 2014;29(6):686–700.

37. Barrete MY, Lusenko S. Hepatic copper-transporting ATPase ATP7B: function and inactivation at the molecular and cellular level. Biometals. 2007;20(3–4):627–637.

38. Deng T, Chen M, Chen T, Thakur A. Expression of the copper transporters hCtr1, ATP7A and ATP7B is associated with the response and survival time in patients with resected non-small cell lung cancer. Cancer Res. 2015;75(10):2844–2850.

39. Li YQ, Chen J, Yin JY, Liu QZ, Li XP. Gene expression and single nucleotide polymorphism of ATP7B are associated with platinum-based chemotherapy response in non-small cell lung cancer patients. J Cancer. 2018;9(19):3532–3539.

40. Fukushima-Uesaka H, Saito Y, Maekawa K, et al. Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients. Drug Metab Pharmacokinet. 2009;24(6):565–574.

41. Schmid SC, Schuster T, Horn T, Gschwend J, Treiber U, Weirich G. Utility of ATP7B in prediction of response to platinum-based chemotherapy in urothelial bladder cancer. Anticancer Res. 2013;33(9):3731–3737.

42. Ji Y, Yang Y, Yin Z. Polymorphisms in IncRNA CCAT1 on the susceptibility of lung cancer in a Chinese northeast population: a case-control study. Cancer Med. 2022. doi:10.1002/cam4.4902.

43. Liu W, Zhang Y, Huang F, et al. The polymorphism and expression of EGFL7 and miR-126 are associated with NSCLC susceptibility. Front Oncol. 2022;12:772405.

44. Yu Y, Mao L, Cheng Z, et al. A novel regQTL-SNP and the risk of lung cancer: a multi-dimensional study. Arch Toxicol. 2021;95(12):3815–3827.